Hawaii 2024 Regular Session

Hawaii Senate Bill SB1454

Introduced
1/25/23  
Refer
1/30/23  
Introduced
1/25/23  
Report Pass
2/17/23  
Refer
1/30/23  
Report Pass
2/17/23  
Report Pass
3/2/23  
Refer
2/17/23  
Engrossed
3/7/23  
Report Pass
3/2/23  
Refer
3/9/23  
Engrossed
3/7/23  

Caption

Relating To Psilocybin.

Impact

The establishment of the Therapeutic Psilocybin Working Group will serve as a collaborative effort involving multiple stakeholders, including health professionals, legal experts, and representatives from relevant state agencies. The group's responsibilities will include examining existing laws, reviewing medical research related to psilocybin, and formulating a long-term plan for the safe and affordable availability of psilocybin products. By anticipating a thoughtful and evidence-based approach, the bill seeks to improve mental health treatment options and fill the gaps created by the shortage of mental health professionals in the state.

Summary

Senate Bill 1454 aims to address the growing mental health crisis in Hawaii by establishing a Therapeutic Psilocybin Working Group. This group is intended to explore the medicinal and therapeutic effects of psilocybin and its effectiveness in treating various mental health conditions such as post-traumatic stress disorder (PTSD), depression, and anxiety. The bill recognizes the potential of psilocybin in mental health treatment, as noted by its designation as a 'breakthrough therapy' by the FDA for treating resistant depression. The successful legalization and implementation of such measures in other states, particularly Oregon and Colorado, serve as a framework for this initiative.

Contention

Despite the perceived benefits, the bill's introduction may stir discussions surrounding the ethical implications of using psilocybin, accessibility of treatment, and regulatory frameworks. Some may express concern over the safety and efficacy of psilocybin as a treatment method, fearing it may trivialize serious health issues or lead to potential misuse. Additionally, funding for the working group and the operational aspects required for implementation may raise questions on budgetary priorities within the state. As the working group is set to report its findings to the legislature before the start of the regular session in 2025, it will be crucial for stakeholders to navigate these discussions collaboratively.

Companion Bills

HI HB1337

Same As Relating To Psilocybin.

HI SB1454

Carry Over Relating To Psilocybin.

Similar Bills

HI SB1454

Relating To Psilocybin.

HI SR153

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI HR206

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI SCR133

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI HCR202

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI HB1337

Relating To Psilocybin.

HI HB1337

Relating To Psilocybin.

HI SR88

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Longterm Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older.